US 11485738
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted A61PA61P35/00
Quick answer
US patent 11485738 (Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors) held by Mirati Therapeutics, Inc. expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P35/00